Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Merck
Dow
Colorcon
Moodys

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020699

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 020699 describes EFFEXOR XR, which is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from six suppliers. Additional details are available on the EFFEXOR XR profile page.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
Summary for 020699
Tradename:EFFEXOR XR
Applicant:Wyeth Pharms
Ingredient:venlafaxine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020699
Suppliers and Packaging for NDA: 020699
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699 NDA Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 0008-0833 0008-0833-03 100 BLISTER PACK in 1 CARTON (0008-0833-03) > 1 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (0008-0833-02)
EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699 NDA Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 0008-0833 0008-0833-20 15 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0008-0833-20)
Paragraph IV (Patent) Challenges for 020699
Tradename Dosage Ingredient NDA Submissiondate
EFFEXOR XR CAPSULE, EXTENDED RELEASE;ORAL venlafaxine hydrochloride 020699 2007-05-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 37.5MG BASE
Approval Date:Oct 20, 1997TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 75MG BASE
Approval Date:Oct 20, 1997TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Oct 20, 1997TE:RLD:No

Expired US Patents for NDA 020699

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997   Start Trial   Start Trial
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997   Start Trial   Start Trial
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997   Start Trial   Start Trial
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997   Start Trial   Start Trial
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997   Start Trial   Start Trial
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-002 Oct 20, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Dow
McKesson
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.